Proteomic analysis of urinary upper gastrointestinal cancer markers

Purpose: We have investigated the use of human urine as a non-invasive medium to screen for molecular biomarkers of carcinomas of the upper gastrointestinal (uGI) tract using SELDI-TOF-MS.

Experimental design: A total of 120 urine specimens from 60 control and 60 uGI cancer patients were analysed to establish a potential biomarker fingerprint for the weak cation exchanger CM10 chip surface, which was validated by blind testing using a further 59 samples from 33 control and 26 uGI cancer patients.

Results: Using Biomarker Pattern software, we established a model with a sensitivity of 98% and specificity of 95% for the learning sample set, and a sensitivity of 96% and specificity of 72% for the validation data set. Model variable importance included six peptides with m/z of 10 230, 10 436, 10 574, 10 311, 10 467, and 1 0118 of which the 10 230 molecular species was the main decider (sensitivity 86% and specificity 80. Initial protein database searching identified 10 230 as S100-A6, 10 436 as S100-P, 10 467 as S100-A9, and 10 574 as S100-A12 of which S100-A6 and S100-A9 were confirmed by Western blotting.

Conclusions and clinical relevance: We have demonstrated that SELDI-TOF-MS as a screening tool is a rapid and valid methodology in the search for urinary cancer biomarkers, and is potentially useful in defining and consolidating biomarker patterns for uGI cancer screening.